La maladie d'Alzheimer (MA) est une pathologie complexe et multifactorielle pour laquelle il n'existe actuellement aucun traitement. Plusieurs hypothèses ont été proposées pour expliquer l'apparition et la progression de cette maladie, dont la cascade amyloïde, qui prédomine dans le domaine de la recherche depuis 30 ans. La voie amyloïdogène nécess...
The emergence of genomics technologies these recent years, especially those combining single-cell resolution and high throughput sequencing, enable us to characterize physiopathological mechanisms at a resolution never achieved before. Single-cell genomics sequencing allow researcher to highlight previously hidden intra-tissue cellular heterogeneit...
International audience
International audience
Alzheimer's disease (AD) is the most common cause of dementia worldwide. Diagnosis during life can be made using imaging and fluid biomarkers reflecting the hallmark lesions including amyloid and tau pathologies, and neurodegeneration. 'Core AD' cerebrospinal fluid (CSF) biomarkers, including measurements of amyloid beta 1-42 (Aß42) and of phosphor...
La maladie d’Alzheimer est la cause la plus courante de démence. Bien que de nombreux essais thérapeutiques visant à empêcher son apparition aient été réalisés ou soient encore en cours, aucun traitement curatif de la maladie n’est à ce jour disponible. Les difficultés rencontrées afin d’établir un traitement ont amené à considérer d’autres approch...
With more than 30 million people diagnosed worldwide, Alzheimer's disease (AD) is the most frequent neurodegenerative disorder. Previous research on murine models of AD highlighted the potential role of cerebral excitatory-inhibitory imbalance in the pathophysiology of AD. Clinical research has since reported that it may give rise to epileptic acti...
With more than 30 million people diagnosed worldwide, Alzheimer's disease (AD) is the most frequent neurodegenerative disorder. Previous research on murine models of AD highlighted the potential role of cerebral excitatory-inhibitory imbalance in the pathophysiology of AD. Clinical research has since reported that it may give rise to epileptic acti...
Alzheimer's disease is characterized by an accumulation of both A-Bêta and tau in the brain causing neurodegeneration. Currently described clearance mechanisms for tau involve the brain glymphatic and lymphatic system from which tau can slowly egress to the blood. However, studies have shown that tau can rapidly reach the blood circulation after in...
Introduction: understanding the progression of neurocognitive disorders in our population remain essential for current care in memory consultation. The main objective of this study was to describe the evolution of cognitive decline in patient attending in a memory clinic.Method: a 7 years longitudinal retrospective and monocentric study was conduct...
